Line of Research: Oncology


The research line includes activities concerning oncologic pathologies of the muscular-skeletal system. The themes concern the definition of (biological, molecular, genetic) prognostic factors in primitive muscular-skeletal tumors, in order to stratify the categories of patients “at risk”, the analysis of mechanisms of resistance to drugs, and the preclinical evaluation of new antitumor drugs or new therapeutic strategies, also including the search for specific targets to be used within the therapy. Specific clinical protocols are defined for these indications too.

We also conduct studies on skeletal tumoral metastases, concerning both the re-absorption mechanisms of the bone tissue and the analysis of mini-invasive techniques (thermoablation with needle/CT-guided) for adjuvant or palliative treatments. The research line will make use of a digitalized Database, collecting over 28.000 cases of tumors and pseudo-tumoral lesions of the muscular-skeletal system; of the Tissue Bank, collecting 2.115 samples of tumoral tissue; and of three national registries: primitive malignant bone tumors, osteosarcomas and LI-Fraumeni syndrome. Finally, in collaboration with the research lines Computer-aided Medicine and Musculoskeletal Regenerative Medicine, we shall quote the studies on the computerized planning of surgical interventions with homeoplastic bone grafting and self-transplants of the vascularized fibula in Orthopedic Oncology; on the following functional evaluation of oncologic patients and on the utilization of mesenchymal stem cells  associated to platelet gel, to improve the integration of massive bone allografts in the reconstructive surgery of the oncologic patient’s skeleton.


The research line pursuits the following objectives:

  • Characterization of muscular-skeletal tumors through genomics and proteomics investigations;
  • Identification of (biological, molecular, genetic) prognostic factors to frame tumors of soft and mineralized tissues of the muscular-skeletal system;
  • Utilization of pharmacogenomics studies aiming to identify the mechanisms of resistance to antitumor drugs and finalization of biomolecular therapies;
  • Preclinical evaluation of new antitumoral drugs, in order to identify focused, selective and less toxic therapeutic strategies;
  • Utilization of perspective studies and clinical revisions addressing an improvement in the diagnostic and therapeutic framing, of both surgical and pharmacological type;
  • Validation of innovative surgical techniques for the treatment of skeletal tumors requiring large resections and functional reconstructions.
Content updated 30/07/2014 - 11:46
Content edited by: Dott. Andrea Paltrinieri (
Utilizza SharethisShareThis  Scrivi una email  Vai a facebook  Vai a twitter